Abstract
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.
Current Topics in Medicinal Chemistry
Title: Thrombolysis for Acute Ischemic Stroke
Volume: 9 Issue: 14
Author(s): M. Uyttenboogaart, J. De Keyser and G. J. Luijckx
Affiliation:
Abstract: In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.
Export Options
About this article
Cite this article as:
Uyttenboogaart M., De Keyser J. and Luijckx J. G., Thrombolysis for Acute Ischemic Stroke, Current Topics in Medicinal Chemistry 2009; 9 (14) . https://dx.doi.org/10.2174/156802609789869655
DOI https://dx.doi.org/10.2174/156802609789869655 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series
Current Drug Safety Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Autoimmune Polyendocrine Syndrome Complicated by Pulmonary Hypertension
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food
Drug Metabolism Letters Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Origin of Chiral Pharmacology Stereochemistry in Metalloprotease Inhibition
Mini-Reviews in Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions
Current Medicinal Chemistry A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Cardiovascular Changes in Menopause
Current Cardiology Reviews Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Mambalgins, the Venom-origin Peptides as a Potentially Novel Group of Analgesics: Mini Review
CNS & Neurological Disorders - Drug Targets Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry The Pharmacologic Approach to the Prevention of Preeclampsia: From Antiplatelet, Antithrombosis and Antioxidant Therapy to Anticonvulsants
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms
Current Medicinal Chemistry The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry